[
  {
    "variant_string_id": "EGFR L858R",
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The paper doesn't explicitly detail a novel disease mechanism related to this functional assay. However, EGFR mutations, including L858R, are well-established drivers of oncogenesis through constitutive activation of the tyrosine kinase receptor, leading to uncontrolled cell proliferation.",
        "judgment": "Yes",
        "reasoning": "EGFR’s role in cancer is widely accepted, providing context for functional assays targeting its activity.",
        "next_step_or_outcome": "Proceed to Step 2"
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "Enzyme activity assays are commonly used to assess the kinase activity of EGFR mutants, directly reflecting their oncogenic potential.  Given that L858R is a well-characterized activating mutation, measuring altered kinase activity is a relevant approach.",
        "judgment": "Yes",
        "reasoning": "Assessing kinase activity is directly related to the disease mechanism – constitutive activation – and a standard method for studying EGFR mutations.",
        "next_step_or_outcome": "Proceed to Step 3"
      },
      {
        "step_name": "Sub-step 3a: Basic Controls and Replicates",
        "extracted_paper_info": "The paper does not mention the use of either Abnormal/Positive/Null controls or state the number of replicates performed. ",
        "judgment": "No",
        "reasoning": "The absence of explicit mention of these critical quality controls raises concerns regarding assay reliability. Neither abnormal controls nor replicates were noted.",
        "next_step_or_outcome": "Proceed to Sub-step 3b"
      },
      {
        "step_name": "Sub-step 3b: Accepted/Validated Assay",
        "extracted_paper_info": "The paper does not mention that this specific instance of the enzyme activity assay has been previously validated in other studies, nor does it reference it as an accepted assay in the field. The assay is performed without detailed description or reference to published protocols.",
        "judgment": "No",
        "reasoning": "Without prior validation or widely accepted status, this instance of the assay cannot immediately be assigned significant weight.",
        "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_supporting"
    },
    "overall_conclusion": "Due to the absence of explicit controls, replicates, prior validation or established acceptance, this observed enzyme activity alteration for EGFR L858R is considered supporting, but not strongly indicative of pathogenicity."
  }
]